Results 1 to 10 of about 318,160 (295)

Angiogenesis Inhibitors in NSCLC. [PDF]

Int J Mol Sci, 2017
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy ...
Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, Piccirillo MC, Daniele G, Perrone F, Rocco G, Morabito A.   +10 more
europepmc   +4 more sources

Protocol development for discovery of angiogenesis inhibitors via automated methods using zebrafish. [PDF]

PLoS One, 2019
Mauro A, Ng R, Li JY, Guan R, Wang Y, Singh KK, Wen XY.   +6 more
europepmc   +1 more source

Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]

Frontiers in Oral Health, 2021
Non peer ...
Abdelhakim Salem, Abdelhakim Salem, Elin Hadler-Olsen, Elin Hadler-Olsen, Ahmed Al-Samadi, Ahmed Al-Samadi   +5 more
doaj   +6 more sources

Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. [PDF]

PLoS ONE, 2013
Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR.
Sabine B Weitensteiner, Johanna Liebl, Vladimir Krystof, Libor Havlíček, Tomáš Gucký, Miroslav Strnad, Robert Fürst, Angelika M Vollmar, Stefan Zahler   +8 more
doaj   +19 more sources

Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? [PDF]

Frontiers in Oncology, 2021
BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression.
Aini Hyytiäinen, Aini Hyytiäinen, Wafa Wahbi, Wafa Wahbi, Otto Väyrynen, Kauko Saarilahti, Peeter Karihtala, Tuula Salo, Tuula Salo, Tuula Salo, Tuula Salo, Tuula Salo, Ahmed Al-Samadi, Ahmed Al-Samadi   +13 more
doaj   +2 more sources

The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis [PDF]

Journal of Ovarian Research, 2022
Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies ...
Chunmei Zhang, Wancheng Zhao
doaj   +2 more sources

Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case‐Control Study [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Research on the cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan is lacking. This observational study explored the risk of major adverse cardiovascular events (MACEs) associated with angiogenesis ...
Yen‐Chou Chen, Chun‐Yao Huang, Li‐Ming Lien, Jin‐Hua Chen, Fang‐I Hsieh   +4 more
doaj   +2 more sources

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma [PDF]

IJU Case Reports, 2020
Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.
Hiroki Hagimoto, Soki Kashima, Kazuki Doi, Shintaro Nakayama, Takanori Sano, Satoshi Imai, Tomihiko Yasufuku, Mototsugu Muramaki, Yuji Yamada   +8 more
doaj   +2 more sources